Cargando…

Utilization and Costs for Compliant Patients Initiating Therapy With Pioglitazone or Rosiglitazone Versus Insulin in a Medicaid Fee-for-Service Population

OBJECTIVES: To compare health care utilization and costs for type 2 diabetes patients initiating therapy with one of two thiazolidinediones (TZDs, pioglitazone or rosiglitazone) or insulin in a Medicaid population. METHODS: The study used a retrospective cohort design and included type 2 diabetes pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalsekar, Iftekhar, Iyer, Shrividya, Mody, Reema, Rajagopalan, Rukmini, Kavookjian, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2006
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437362/ https://www.ncbi.nlm.nih.gov/pubmed/16515370 http://dx.doi.org/10.18553/jmcp.2006.12.2.121

Ejemplares similares

Development of Heart Failure in Medicaid Patients with Type 2 Diabetes Treated with Pioglitazone, Rosiglitazone, or Metformin
por: Breunig, Ian M., et al.
Publicado: (2014)

Medicaid Fees and the Medicare Fee Schedule: An Update
por: Norton, Stephen A.
Publicado: (1995)

The Impact of Medicaid Adoption of the Medicare Fee Schedule
por: Holahan, John, et al.
Publicado: (1993)

Rosiglitazone and Pioglitazone Alter Aromatase Kinetic Properties in Human Granulosa Cells
por: Araki, Takako, et al.
Publicado: (2011)

Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings
por: Niyomnaitham, Suvimol, et al.
Publicado: (2014)

Rosiglitazone and Pioglitazone Utilization from January 2007 Through May 2008 Associated With Five Risk-Warning Events
por: Starner, Catherine I., et al.
Publicado: (2008)

Children's Mental Health Services in Fee-for-Service Medicaid
por: Larson, Mary Jo, et al.
Publicado: (2004)

Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy
por: Nadkarni, Anagha, et al.
Publicado: (2013)

Utilization of smoking cessation medication benefits among medicaid fee-for-service enrollees 1999–2008
por: Kahende, Jennifer, et al.
Publicado: (2017)

ACE Inhibitor and ARB Utilization and Expenditures in the Medicaid Fee-For-Service Program from 1991 to 2008
por: Bian, Boyang, et al.
Publicado: (2010)

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study
por: Juurlink, David N, et al.
Publicado: (2009)

Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies
por: Deeg, Mark A., et al.
Publicado: (2008)

Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database
por: Berthet, Stephanie, et al.
Publicado: (2011)

Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs
por: Colhoun, H. M., et al.
Publicado: (2012)

Influence of health warnings on the use of rosiglitazone and pioglitazone in an area of Spain: A time-series study
por: Carracedo-Martínez, Eduardo, et al.
Publicado: (2016)

State Medicaid Programs Bring Managed Care Tenets to Fee for Service
por: Keast, Shellie L., et al.
Publicado: (2016)

Dual therapy of rosiglitazone/pioglitazone with glimepiride on diabetic nephropathy in experimentally induced type 2 diabetes rats
por: Rao, Ravi Prakash, et al.
Publicado: (2011)

Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer
por: Hernandez, Inmaculada, et al.
Publicado: (2020)

The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety
por: Leonard, Charles E., et al.
Publicado: (2020)

Healthcare Utilization and Costs of Systemic Lupus Erythematosus in Medicaid
por: Kan, Hong J., et al.
Publicado: (2013)

Coverage of genetic therapies for spinal muscular atrophy across fee-for-service Medicaid programs
por: Ballreich, Jeromie, et al.
Publicado: (2022)

Medicaid professional fees for treatment of opioid use disorder varied widely across states and were substantially below fees paid by medicare in 2021
por: Clemans-Cope, Lisa, et al.
Publicado: (2022)

Factors Associated With Emergency Department Visits: A Multistate Analysis of Adult Fee-for-Service Medicaid Beneficiaries
por: Agarwal, Parul, et al.
Publicado: (2016)

The Estimated Impact of Drug Importation, Mandatory Mail Service, and Medicaid Fee Reduction on Community Pharmacies in Michigan
por: McKercher, Patrick L.
Publicado: (2006)

Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet
por: Kus, Vladimir, et al.
Publicado: (2011)

The Medicaid Cost of Palivizumab
por: Ambrose, Christopher S., et al.
Publicado: (2015)

The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication
por: Frois, Christian, et al.
Publicado: (2013)

The impact of acute rosiglitazone on insulin pharmacokinetics at the blood‐brain barrier
por: Galindo, Demi C., et al.
Publicado: (2020)

Medicaid Highlights: Trends in Medicaid Prescribed Drug Expenditures and Utilization
por: Tepper, Carl D., et al.
Publicado: (2004)

Professional Fees and Fee Bills
por: Dawbarn, Robert H. M.
Publicado: (1906)

Leukemia and rosiglitazone
por: Yavasoglu, Irfan, et al.
Publicado: (2016)

Long-term acute care hospitals and Georgia Medicaid: Utilization, outcomes, and cost
por: Cole, Evan S., et al.
Publicado: (2016)

Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan
por: Corelli, Robin L., et al.
Publicado: (2021)

Changes in Medicaid Fee-for-Service Benefit Design for Substance Use Disorder Treatment During the Opioid Crisis, 2014 to 2021
por: Shoulders, Angela, et al.
Publicado: (2023)

Cost plus fee and target estimate contracts (COC)
por: CERN. Geneva. Super Proton Synchrotron Division (SPS)
Publicado: (No d)

Fees
Publicado: (1880)

Fees
por: Trotter, W. C.
Publicado: (1904)

Fees
por: Jennings, D. R.
Publicado: (1870)

Healthcare Costs Among Adults with Type 2 Diabetes Initiating DPP-4 Inhibitors
por: Farr, Amanda M., et al.
Publicado: (2016)

The Janus face of rosiglitazone
por: Pich, Christine, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9brfk71mj2jk712ji2ig8tl5gb